Piper Jaffray Upgrades BioForm Medical (BFRM) to Overweight; Worst of Aesthetic Storm Have Passed
More News related to BFRM
- BioForm Medical and Galderma Laboratories Chiefs to Make Opening Keynote Address on Leadership at Orlando Dermatology Aesthetic & Clinical Conference
- Piper Jaffray Upgrades BioForm Medical (BFRM) to Overweight; Worst of Aesthetic Storm Have Passed
- BioForm Medical Reports Financial Results for Quarter Ended September 30, 2009, First Quarter of Fiscal 2010
- Bioform Medical Announces Earnings Call on November 2, 2009, and Presentation at Upcoming Investor Conference
- Piper Jaffray Upgrades BioForm Medical (BFRM) to Neutral; Holding Their Own Against Larger Players
Piper Jaffray & Co. upgrades BioForm Medical (Nasdaq: BFRM) to Overweight. Price target increased from $4 to $5.
Piper analyst says, "BFRM reported FQ1 (Sept) revenues of $18.3M, above our Street high $16.4M estimate and was cash flow positive for the 2nd quarter in a row. The bump in sales was largely due to continued success of BFRM's new marketing strategy. With $42.9M in cash, minimal (if any) cash burn expected, new indications and new products in the pipeline for CY10, we believe BFRM will be well positioned once consumer sentiment rebounds. We are raising our rating to Overweight as the worst of the aesthetic storm seems to have passed."
To see more analyst ratings on BFRM Click Here.
BioForm Medical, Inc., a medical aesthetics company, focuses on developing and commercializing products that are used by physicians to enhance a patientÂ’s appearance.
Related Categories
UpgradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
